BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its first authorization in December 2020, and its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships. BioNTech has also used cash from its covid vaccine profits to acquire rights to a more diversified pipeline of biologic drug candidates in oncology, with launches potentially starting in 2026.